Cognition Therapeutics Gestione
Criteri Gestione verificati 3/4
Cognition Therapeutics Il CEO è Lisa Ricciardi, nominato in Mar2020, e ha un mandato di 6.25 anni. la retribuzione annua totale è $ 1.46M, composta da 44.6% di stipendio e 55.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.56% delle azioni della società, per un valore di $ 600.56K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 6.6 anni.
Informazioni chiave
Lisa Ricciardi
Amministratore delegato
US$1.5m
Compenso totale
| Percentuale dello stipendio del CEO | 44.60% |
| Mandato del CEO | 6.3yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 3.3yrs |
| Durata media del Consiglio di amministrazione | 6.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaIs Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$20m |
| Dec 31 2025 | US$1m | US$651k | -US$23m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$33m |
| Mar 31 2025 | n/a | n/a | -US$33m |
| Dec 31 2024 | US$2m | US$629k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$31m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$587k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$550k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$11m | US$409k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$1m | US$287k | -US$12m |
Compensazione vs Mercato: La retribuzione totale di Lisa ($USD 1.46M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.34K ).
Compensazione vs guadagni: La retribuzione di Lisa è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Lisa Ricciardi (66 yo)
Ms. Lisa R. Ricciardi serves as Chief Executive Officer and President at Cognition Therapeutics, Inc. since March 2020 and as Director since March 2019. She serves as an Independent Non-Executive Director...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 6.3yrs | US$1.46m | 0.56% $ 600.6k | |
| Chief Financial Officer | 3.1yrs | US$866.79k | 0.69% $ 748.9k | |
| Chief Medical Officer | 7.2yrs | US$927.89k | 0.29% $ 312.3k | |
| VP & Head of CMC | 2.9yrs | Nessun dato | Nessun dato | |
| Head of Quality | 2.4yrs | Nessun dato | Nessun dato | |
| Corporate Controller | 3.4yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di CGTX è considerato esperto (durata media dell'incarico 3.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 7.3yrs | US$1.46m | 0.56% $ 600.6k | |
| Independent Director | 4.6yrs | US$68.52k | 0.027% $ 29.6k | |
| Independent Chairman of the Board | 5.9yrs | US$95.02k | 0.016% $ 17.5k | |
| Independent Director | 9.8yrs | US$61.02k | 0.059% $ 63.5k | |
| Member of Medical Advisory Board | 4.4yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.7yrs | US$64.52k | 0.016% $ 17.5k | |
| Independent Director | 10.9yrs | US$59.52k | 0.025% $ 26.9k | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific & Biomarker Advisory Board | 7.6yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisor Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CGTX sono considerati esperti (durata media dell'incarico 6.6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/09 07:18 |
| Prezzo dell'azione a fine giornata | 2026/06/09 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cognition Therapeutics, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |